Trial Profile

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glecaprevir/pibrentasvir (Primary)
Indications Hepatitis C
Focus Therapeutic Use
Acronyms QUICK-CURE

Most Recent Events

03 Dec 2024 Status changed from completed to discontinued. (Unable to meet enrollment goal prior to drug expiration)
06 Oct 2023 Status changed from recruiting to completed.
10 May 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com